Pasar al contenido principal

IDENTIFICACION DE NUEVAS DIANAS TERAPEUTICAS PARA EL TRATAMIENTO DEL CARCINOMA HEPATOCELULAR: ANALISIS DE LA FUNCION DE LA CATEPSINA D EN EL EJE INFLAMACION-FIBROSIS-CANCER

RTI2018-097475-A-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

  • Martínez García de la Torre, Raquel A.
  • Ayuso García, Paula
  • Varela Rey, Marta María
  • Woodhoo, Ashwin
  • Sancho-Bru, Pau
Defining the trajectory of cells during differentiation and disease is key for uncovering the mechanisms driving cell fate and identity. However, trajectories of human cells remain largely unexplored due to the challenges of studying them with human samples. In this study, we investigate the proteome trajectory of iPSCs differentiation to hepatic stellate cells (diHSCs) and identify RORA as a key transcription factor governing the metabolic reprogramming of HSCs necessary for diHSCs’ commitment, identity, and activation. Using RORA deficient iPSCs and pharmacologic interventions, we show that RORA is required for early differentiation and prevents diHSCs activation by reducing the high energetic state of the cells. While RORA knockout mice have enhanced fibrosis, RORA agonists rescue multi-organ fibrosis in in vivo models. Notably, RORA expression correlates negatively with liver fibrosis and HSCs activation markers in patients with liver disease. This study reveals that RORA regulates cell metabolic plasticity, important for mesoderm differentiation, pericyte quiescence, and fibrosis, influencing cell commitment and disease.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The multifaceted role of cathepsins in liver disease

  • Ruiz-Blázquez, Paloma
  • Pistorio, Valeria
  • Fernández-Fernández, María
  • Moles, Anna
Proteases are the most abundant enzyme gene family in vertebrates and they execute essential functions in all living organisms. Their main role is to hydrolase the peptide bond within proteins, a process also called proteolysis. Contrary to the conventional paradigm, proteases are not only random catalytic devices, but can perform highly selective and targeted cleavage of specific substrates, finely modulating multiple essential cellular processes. Lysosomal protease cathepsins comprise 3 families of proteases that preferentially act within acidic cellular compartments, but they can also be found in other cellular locations. They can operate alone or as part of signalling cascades and regulatory circuits, playing important roles in apoptosis, extracellular matrix remodelling, hepatic stellate cell activation, autophagy and metastasis, contributing to the initiation, development and progression of liver disease. In this review, we comprehensively summarise current knowledge on the role of lysosomal cathepsins in liver disease, with a particular emphasis on liver fibrosis, non-alcoholic fatty liver disease and hepatocellular carcinoma., AM’s research was supported by a “Research Challenges" R+D+i Project (RTI2018-097475-A-100) and a Ramon y Cajal contract (RYC-2016-19731) awarded by FEDER/Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación. PRB is supported by a FPU PhD studentship (FPU19/05357) funded by Ministerio de Ciencia, Innovación y Universidades. VP held a PhD studentship funded by University of Naples Federico II. MFF salary was supported by JAE Intro fellowship (JAEINT_20_02409) from the Spanish National Research Council (CSIC) and FI AGAUR (2021 FI_B 00249).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysosomal hydrolases, from waste-bags effectors to essential multipurpose enzymes in liver fibrosis

  • Fernández-Fernández, María
  • Ruiz-Blázquez, Paloma
  • Cacho-Pujol, Júlia
  • Moles, Anna
Lysosomal hydrolases were once considered effectors of the waste disposal system of the cell, the endo-lysosomal system. However, they are now recognized as highly selective enzymes, which can modulate the function of several substrates, contributing to essential homeostatic and pathological cellular processes. There are more than 50 different lysosomal hydrolases that display optimal activity in the pH present in the acidic cellular compartment but can also be found in other cellular locations. They can work alone or in cooperation with other proteases building signaling pathways or amplification cascades. In the context of liver fibrosis lysosomal hydrolases, especially cysteine cathepsins have been described to participate in several fundamental cellular events contributing to the development, progression, perpetuation, and resolution of liver fibrosis. This paper comprehensively reviews the current knowledge on the contribution of lysosomal hydrolases to liver fibrosis., AM’s research is supported by grants [RTI2018-097475-A-100] and [PID2021-123652OB-I00] funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Both MFF and PRB salaries were supported by FPU fellowships ([FPU20/01367] and [FPU19/05357], respectively) awarded by the Ministry of Universities, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Searching for novel cellular targets for MASLD and HCC within the humble lysosomal cathepsins

  • Castillo-Cruz, Alejandro del
  • Fernández-Fernández, María
  • Moles, Anna
Metabolic-associated steatotic liver disease (MASLD) and its pathological version, metabolic dysfunction-associated steatohepatitis (MASH), are becoming the main leading causes of chronic liver disease almost worldwide and are the fastest growing aetiology of hepatocellular carcinoma (HCC), especially in the Western countries. The combination of high incidence and morbidity with limited treatment options for both MASH and HCC highlights an urgent need for the discovery of novel therapeutic candidates to inform drug development. The importance of lysosomes and cathepsins, their most abundant hydrolases, has been overlooked for decades. They were considered organelles only involved in the recycling of macromolecules, with cathepsins simply being their effectors. Contrary to this traditional view, recent findings have shed new light on the lysosome and its enzymes as drivers of essential cellular processes, such as apoptosis and autophagy. Bringing lysosomal activity and the regulation of cathepsins into the spotlight of MASH and HCC research can open new avenues for the development of novel drugs based on targeting cathepsin-driven lysosomal activity and its associated pathological processes. This review comprehensively summarises the current knowledge on the role and contribution of lysosomal cathepsins to MASLD/MASH and HCC progression., This work was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants [PID2021-123652OB-I00] and [RTI2018-097475-A-100] (AM); by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract [RYC-2016-19731] (AM); by Pfizer grant [#77131383] (AM); by CSIC contract [JAEINT_23_01245] (AdCC); and by Ministerio de Universidades, Spain contract [FPU20/01367] (MFF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease

  • Ariño, Silvia
  • Ferrer-Lorente, Raquel
  • Serrano, Guillermo
  • Zanatto, Laura
  • Martínez-García de la Torre, Raquel A.
  • Gratacós-Ginès, Jordi
  • Rubio, Ana Belén
  • Pérez, Martina
  • Mateos-Sánchez, Carlos
  • Aguilar-Bravo, Beatriz
  • Atkinson, Stephen
  • Xu, Zhengqing
  • Cantallops-Vilà, Paula
  • Sererols-Viñas, Laura
  • Ruiz-Blázquez, Paloma
  • Rill, Aina
  • Fundora, Yiliam
  • Lozano, Juan José
  • Coll, Mar
  • Ochoa, Idoia
  • Affo, Silvia
  • Moles, Anna
  • Mereu, Elisabetta
  • Bataller, Ramón
  • Pose, Elisa
  • Sancho-Bru, Pau
Animal models poorly recapitulate advanced alcohol-associated liver disease (ALD), precluding the development of new treatments. Organoids have emerged as a powerful human-based preclinical tool; however, current patient-derived liver organoids fail to capture epithelial heterogeneity and require surgical resections, limiting their use in personalized disease modeling. Here, we describe the development of organoids from liver needle biopsies (b-Orgs) obtained from patients with ALD., This work has been supported by grants to P.S-B. Proyecto PI20/00765 and PI23/00724, funded by “Instituto de Salud Carlos III (ISCIII) co-financed by the European Union. By HORIZON-HLTH-2022- STAYHLTH-02, grant number 101095679, funded by the European Union. Project FORT23/00002, funded by Instituto de Salud Carlos III (ISCIII) "Programa FORTALECE del Ministerio de Ciencia, Innovación y Universidades". This work has also been co-financed for P.S-B by the Spanish Ministry of Science and Innovation with funds from the European Union NextGenerationEU, from the Recovery, Transformation and Resilience Plan (PRTR-C17.I1) and from the Autonomous Community of Catalonia within the framework of the Biotechnology Plan Applied to Health (Q6922). S.A. received a fellowship from the Ministerio de Educación, Cultura y Deporte (FPU17/04992). R.A. M-G. was funded by the Instituto de Salud Carlos III, PFIS (FI18/00215). B.A-B. was funded by Instituto de Salud Carlos III, PFIS (FI16/00203). M.C. is funded by the Ramon y Cajal program from the Ministerio de Ciencia e Innovación RYC2019-026662-I and by the State Plan of Scientific and Technical Research and Innovation PID2021-125195OB-I00. S.A. is funded by the MCIN/AEI/10.13039/501100011033 by “ERDF A way of making Europe” (PID2021-124694OA-I00) and the European Union grant agreement 101077312. A.M. was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100; by MCIN/AEI/10.13039/501100011033; by Pfizer grant #77131383; and the contract RYC-2016-19731. P.R-B received a fellowship from the Spanish Ministry of Education, Culture and Sports, FPU program (FPU19/05357)., Peer reviewed